444792-41-0

Upstream product

• 944355-56-0 2-bromo-N-(2-hydroxy-4-methylphenyl)-2-phenylacetamide 
• 19078-72-9 bromo(phenyl)acetyl chloride 
• 2835-98-5 2-Hydroxy-4-methylanilin 

Downstream Products

• 944355-79-7 7-methyl-2-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1331947-79-5 7-methyl-4-nitroso-2-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 1331947-83-1 7-methyl-2-phenyl-N-(propan-2-ylidene)-2H-benzo[b][1,4]oxazin-4(3H)-amine 

Relevant academic research and scientific papers

FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Carboxylic Acid Compounds and Use Thereof

Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: [image] wherein each symbol is as defined in the specification.